Zhejiang Shapuaisi Pharmaceutical Co (603168) Fair Value & Analysis
Healthcare · CN · Market cap 2.0B CNY
Fair value as of: Jul 11, 2026
From 4 valuation models · updated today
Fair value updated Jul 11, 2026 — revised from ¥16.25 to ¥2.03 (−87.5%) since Jun 24, 2026. Share price −8.1% over the past month.
Price vs Fair Value (12 months)
12‑month range ¥4.59 – ¥8.37 · fair‑value band ¥1.42 – ¥2.63 · the ¥4.81 price screens above the ¥2.03 fair value. As of Jul 11, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Zhejiang Shapuaisi Pharmaceutical Co (603168) currently trades at ¥4.81, while our model-based Fair Value estimate is ¥2.03 — implying the stock looks roughly 57.8% overvalued today. We read business quality at 30/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, Zhejiang Shapuaisi Pharmaceutical Co generated revenue of 460M CNY at a net margin of -59.6%. Revenue declined 3.2% year over year. It earns a return on equity of -18.7%. Net debt stands at 146M CNY. Fundamentals as of Jul 11, 2026
Our scenario range runs from ¥1.42 (bear case) to ¥2.63 (bull case); at ¥4.81, the current price sits above that range. The share trades about 47% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -48% fair-value upside — at -58%, 603168 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 11, 2026. TTM = trailing twelve months.
About the company
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceutical products. The company provides its products to ophthalmology, antimicrobials, gynecology, and other classes. It offers its products in injections, oral solutions, eye drops, large-volume injections, oral solutions, tablets, granules, and other dosage forms. It also offers medical and health care, and scientific research and teaching facilities. Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. was founded in 2000 and is based in Pinghu, China.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Zhejiang Shapuaisi Pharmaceutical Co reported revenue of ¥463M in FY2025 versus ¥630M in FY2021, a compound −7.4%/yr. Reported net income was −¥239M in FY2025.
Is 603168 fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 11, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$26.19 | R$26.01 | -1% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,788 | ₹2,035 | -70% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,421 | ₹1,504 | -66% |
| Cipla Limited CIPLA | ₹1,401 | ₹592.37 | -58% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,098 | ₹507.31 | -54% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,272 | ₹720.15 | -43% |
| Lupin Limited LUPIN | ₹2,340 | ₹2,477 | +6% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Zhejiang Shapuaisi Pharmaceutical Co (603168) undervalued?
What is the fair value of 603168?
What is the quality score of 603168?
What is the revenue of Zhejiang Shapuaisi Pharmaceutical Co (603168)?
What is the net profit margin of 603168?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
The 25 strongest value stocks, free every month
Enter your email to get the free monthly Top-25 report of the most undervalued quality stocks from 35,000+ analysed. Unsubscribe anytime.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.